Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

BlackThorn begins Phase IIa of BTRX-246040 for MDD

July 28, 2017 6:32 AM UTC

BlackThorn Therapeutics Inc. (South San Francisco, Calif.) began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate BTRX-246040 for 8 weeks in about 100 patients with major depressive disorder (MDD) with or without anhedonia. Patients will receive once-daily 40 mg oral BTRX-246040 for the first week followed by once-daily 80 mg oral BTRX-246040 for weeks 2-8...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article